YI-SHUAN SHEENCHIA-YU CHUYu H.-S.2019-12-042019-12-0420060003-987Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33746064910&doi=10.1001%2farchderm.142.7.879&partnerID=40&md5=6cb5ef343bf85973477871e0d5670e6fhttps://scholars.lib.ntu.edu.tw/handle/123456789/434985Administration of propylthiouracil therapy has been associated with a hypersensitivity syndrome that typically manifests as vasculitis. 1 Most cases of propylthiouracil therapy-induced antineutrophil cytoplasmic antibody (ANCA) positivity react to perinuclear ANCA (p-ANCA). 1 We describe a patient who presented with cutaneous manifestations of propylthiouracil therapy hypersensitivity vasculitis with ANCA positivity. ?2006 American Medical Association. All rights reserved.[SDGs]SDG3neutrophil cytoplasmic antibody; propylthiouracil; adult; article; case report; clinical feature; female; histopathology; human; human tissue; immunofluorescence; leukocytoclastic vasculitis; priority journal; skin biopsy; skin disease; Adult; Antibodies, Antineutrophil Cytoplasmic; Antithyroid Agents; Arm; Diagnosis, Differential; Drug Eruptions; Ear, External; Female; Heel; Humans; Hyperthyroidism; Propylthiouracil; Vasculitis, Hypersensitivityjournal article10.1001/archderm.142.7.879168472042-s2.0-33746064910